[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@AlfredoM617 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::47191740.png) @AlfredoM617 Alfredo M

Alfredo M posts on X about $vktx, $1b, rates, q2 the most. They currently have XXX followers and XXX posts still getting attention that total X engagements in the last XX hours.

### Engagements: X [#](/creator/twitter::47191740/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47191740/c:line/m:interactions.svg)

- X Week XXX -XX%
- X Month XXXXXX +6,129%
- X Months XXXXXXX +642%
- X Year XXXXXXX +3,626%

### Mentions: X [#](/creator/twitter::47191740/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47191740/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX +663%
- X Months XXX +198%
- X Year XXX +1,043%

### Followers: XXX [#](/creator/twitter::47191740/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47191740/c:line/m:followers.svg)

- X Week XXX -XXXX%
- X Month XXX +8.80%
- X Months XXX +129%
- X Year XXX +131%

### CreatorRank: undefined [#](/creator/twitter::47191740/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47191740/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::47191740/influence)
---

**Social category influence**
[cryptocurrencies](/list/cryptocurrencies) 

**Social topic influence**
[$vktx](/topic/$vktx), [$1b](/topic/$1b), [rates](/topic/rates), [q2](/topic/q2), [$eco](/topic/$eco), [$cldx](/topic/$cldx), [reset](/topic/reset), [voyage](/topic/voyage), [$vik](/topic/$vik), [$aaon](/topic/$aaon)

**Top assets mentioned**
[Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Ormeus Ecosystem (ECO)](/topic/$eco) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx) [Viking Holdings Ltd (VIK)](/topic/$vik) [Aaon Inc (AAON)](/topic/$aaon)
### Top Social Posts [#](/creator/twitter::47191740/posts)
---
Top posts by engagements in the last XX hours

"$ECO Q2 2025: Suezmax Rates Surge XX% as Young Fleet and Oil Flows Reshape Tanker Upside Spot Rate Windfall from Tight Supply: $ECO locked in Suezmax spot rates of $60600 per day as OPEC shifts and aging fleets drive scarcity giving its young eco-compliant tankers a pricing edge. Strategic Leverage on Volatility: Full spot exposure and low-cost capital structure position $ECO to capture upside from geopolitical shifts rising asset values and long-haul oil trade demand"  
![@AlfredoM617 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::47191740.png) [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1941978148385521967) 2025-07-06 21:50:45 UTC XXX followers, XXX engagements


"$CLDX delivers XX% sustained response in CSU raising bar for biologics Barzavolumab showed XX% complete response at X months post-treatment in severe CSU patients the most durable result in the field to date. High retention and broad applicability position it to disrupt CSU therapy ahead of pivotal phase X readout in 2026"  
![@AlfredoM617 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::47191740.png) [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1942305194210914498) 2025-07-07 19:30:19 UTC XXX followers, XXX engagements


"VK2809: A Potential Breakthrough in NASH and Cardiometabolic Disease $VKTX While VK2735 leads headlines VK2809 deserves its own spotlight. This is a liver-selective thyroid hormone receptor- (TR) agonist developed for nonalcoholic steatohepatitis (NASH) a chronic progressive liver disease with no FDA-approved drug. Phase 2b Results: Arguably Best-in-Class In its 52-week VOYAGE trial VK2809 hit multiple histological and metabolic endpoints: XX% achieved NASH resolution (vs XX% placebo) XX% showed fibrosis improvement (vs XX% placebo) XX% achieved both a rare dual endpoint success LDL and"  
![@AlfredoM617 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::47191740.png) [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843363745980647) 2025-07-14 19:36:06 UTC XXX followers, XXX engagements


"Viking $VKTX Is Not Just Another GLP-1 Play Viking Therapeutics is one of the most underappreciated pipeline stories in biotech. It has: A dual-form GLP-1/GIP agonist that may be best-in-class A NASH drug with market-leading data and lipid benefits A rare disease candidate that could be first-in-class $1B in cash allowing it to go to market alone or with leverage Strong clinical and mechanistic de-risking Multiple paths to monetization including partnership or M&A In short Viking could evolve from a clinical-stage innovator to a dominant metabolic franchise or become the most lucrative buyout"  
![@AlfredoM617 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::47191740.png) [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843369181561151) 2025-07-14 19:36:07 UTC XXX followers, 1354 engagements


"$AAON $1B backlog shows how fast demand is shifting to data center cooling and next-gen heat pumps. Old rooftop systems are slowing down but strong orders and new tech are driving growth. Key: turning that backlog into profit and widening their customer base in 2025"  
![@AlfredoM617 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::47191740.png) [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1941495606301929932) 2025-07-05 13:53:18 UTC XXX followers, XXX engagements